Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy ARWR Stock  Free ARWR Stock Alerts

Arrowhead Pharmaceuticals (ARWR) Financials

Arrowhead Pharmaceuticals logo
$15.13 -0.26 (-1.69%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$15.32 +0.18 (+1.22%)
As of 05/23/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Arrowhead Pharmaceuticals

Annual Income Statements for Arrowhead Pharmaceuticals

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 9/30/2024 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019 9/30/2018 9/30/2017 9/30/2016 9/30/2015 9/30/2014
Net Income / (Loss) Attributable to Common Shareholders		 -599 -205 -176 -141 -85 68 -54 -34 -82 -92 -59
Consolidated Net Income / (Loss)		 -610 -209 -176 -141 -85 68 -54 -34 -82 -92 -59
Net Income / (Loss) Continuing Operations		 -610 -209 -176 -141 -85 68 -54 -34 -82 -92 -59
Total Pre-Tax Income 		-612 -206 -173 -141 -85 68 -54 -34 -82 -92 -59
Total Operating Income		 -601 -205 -179 -149 -93 61 -56 -37 -82 -96 -53
Total Gross Profit		 3.55 241 243 138 88 169 16 31 0.16 0.38 0.18
Total Revenue		 3.55 241 243 138 88 169 16 31 0.16 0.38 0.18
Operating Revenue		 3.55 241 243 138 88 169 16 31 0.16 0.38 0.18
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 605 446 422 287 181 108 72 68 82 96 53
Selling, General & Admin Expense		 99 93 124 81 52 27 19 17 24 24 19
Research & Development Expense		 506 353 297 206 129 81 53 51 62 57 23
Total Other Income / (Expense), net		 -11 -1.49 5.80 8.19 8.61 6.96 1.49 2.62 0.02 4.04 -5.44
Interest Expense		 32 18 0.00 0.00 - - - - - - -
Interest & Investment Income		 23 15 5.03 6.12 9.19 6.96 1.05 0.42 0.27 0.73 0.57
Other Income / (Expense), net		 -1.75 1.54 0.77 2.07 -0.58 0.00 0.44 2.20 -0.24 3.31 -5.95
Income Tax Expense		 -2.77 2.78 3.79 0.00 0.00 0.17 0.00 0.00 0.00 0.00 0.01
Net Income / (Loss) Attributable to Noncontrolling Interest		 -10 -4.00 -0.43 0.00 0.00 - - - - - -0.10
Basic Earnings per Share		 ($5.00) ($1.92) ($1.67) ($1.36) ($0.84) $0.72 ($0.65) ($0.47) ($1.34) ($1.60) ($1.25)
Weighted Average Basic Shares Outstanding		 119.78M 106.75M 105.43M 103.75M 100.72M 93.86M 83.64M 73.90M 61.05M 57.36M 46.93M
Diluted Earnings per Share		 ($5.00) ($1.92) ($1.67) ($1.36) ($0.84) $0.69 ($0.65) ($0.47) ($1.34) ($1.60) ($1.25)
Weighted Average Diluted Shares Outstanding		 119.78M 106.75M 105.43M 103.75M 100.72M 98.61M 83.64M 73.90M 61.05M 57.36M 46.93M
Weighted Average Basic & Diluted Shares Outstanding		 124.43M 107.43M 106.01M 104.53M 102.76M 95.71M 83.64M 73.90M 61.05M 57.36M 46.93M

Quarterly Income Statements for Arrowhead Pharmaceuticals

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -173 -171 -171 -125 -133 -110 -103 49 -41 -86 -72
Consolidated Net Income / (Loss)		 -175 -173 -174 -127 -135 -111 -104 48 -42 -86 -72
Net Income / (Loss) Continuing Operations		 -175 -173 -174 -127 -135 -111 -104 48 -42 -86 -72
Total Pre-Tax Income 		-175 -173 -174 -127 -139 -109 -103 48 -42 -82 -72
Total Operating Income		 -161 -162 -176 -126 -137 -108 -103 48 -42 -84 -73
Total Gross Profit		 2.50 - 0.00 0.00 3.55 16 16 146 63 32 32
Total Revenue		 2.50 - 0.00 0.00 3.55 16 16 146 63 32 32
Operating Revenue		 2.50 - 0.00 0.00 3.55 16 16 146 63 32 32
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 164 162 176 126 140 124 119 98 105 115 105
Selling, General & Admin Expense		 27 26 24 25 24 25 24 23 21 32 33
Research & Development Expense		 137 136 152 101 116 100 95 75 84 83 72
Total Other Income / (Expense), net		 -14 -11 2.16 -0.81 -2.14 -0.66 -0.68 -0.49 0.34 1.67 0.86
Interest Expense		 22 15 5.09 7.24 5.37 5.26 5.16 5.06 2.85 - 0.00
Interest & Investment Income		 7.60 7.17 6.50 6.25 2.80 3.89 4.17 4.56 2.68 1.58 1.24
Other Income / (Expense), net		 0.34 -3.12 0.76 0.19 0.42 0.72 0.31 0.01 0.51 0.09 -0.38
Income Tax Expense		 0.10 0.55 0.00 0.00 -3.31 2.04 0.74 0.00 0.00 3.79 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -2.13 -2.81 -3.18 -1.70 -2.51 -1.34 -1.18 -1.00 -0.49 -0.43 0.00
Basic Earnings per Share		 ($1.39) ($1.36) ($1.38) ($1.02) ($1.24) ($1.03) ($0.96) $0.46 ($0.39) ($0.81) ($0.68)
Weighted Average Basic Shares Outstanding		 124.85M 119.78M 124.20M 123.29M 107.42M 106.75M 107.00M 106.76M 106.04M 105.43M 105.75M
Diluted Earnings per Share		 ($1.39) ($1.36) ($1.38) ($1.02) ($1.24) ($1.02) ($0.96) $0.45 ($0.39) ($0.80) ($0.68)
Weighted Average Diluted Shares Outstanding		 124.85M 119.78M 124.20M 123.29M 107.42M 106.75M 107.00M 108.14M 106.04M 105.43M 105.75M
Weighted Average Basic & Diluted Shares Outstanding		 126.10M 124.43M 124.32M 124.20M 123.90M 107.43M 107.19M 106.90M 108.31M 106.01M 105.85M

Annual Cash Flow Statements for Arrowhead Pharmaceuticals

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 9/30/2024 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019 9/30/2018 9/30/2017 9/30/2016 9/30/2015 9/30/2014
Net Change in Cash & Equivalents		 -12 3.01 -76 41 -79 192 5.29 -61 4.15 -51 113
Net Cash From Operating Activities		 -463 -154 -136 171 -96 173 -47 -24 -64 -66 -35
Net Cash From Continuing Operating Activities		 -463 -154 -136 171 -96 173 -47 -24 -64 -66 -35
Net Income / (Loss) Continuing Operations		 -610 -209 -176 -141 -85 68 -54 -34 -82 -92 -59
Consolidated Net Income / (Loss)		 -610 -209 -176 -141 -85 68 -54 -34 -82 -92 -59
Depreciation Expense		 19 12 10 8.27 5.94 4.44 4.70 4.69 3.26 2.34 1.35
Amortization Expense		 -3.24 -2.02 2.91 0.27 0.53 1.07 0.38 -0.04 0.23 1.11 0.79
Non-Cash Adjustments To Reconcile Net Income		 109 143 139 78 44 12 8.45 7.89 14 20 7.84
Changes in Operating Assets and Liabilities, net		 23 -98 -112 225 -62 87 -6.31 -2.10 0.16 2.43 13
Net Cash From Investing Activities		 -420 -96 -5.42 -142 -241 -48 -7.43 -49 13 14 -36
Net Cash From Continuing Investing Activities		 -420 -96 -5.42 -142 -241 -48 -7.43 -49 13 14 -36
Purchase of Property, Plant & Equipment		 -141 -177 -53 -24 -12 -12 -1.42 -7.92 -3.86 -12 -1.72
Purchase of Investments		 -721 -246 -223 -241 -279 -90 -52 -45 0.00 0.00 -46
Sale and/or Maturity of Investments		 442 327 271 123 50 55 46 4.25 17 26 12
Net Cash From Financing Activities		 871 253 65 11 258 66 60 12 55 0.29 185
Net Cash From Continuing Financing Activities		 871 253 65 11 258 66 60 12 55 0.29 185
Repayment of Debt		 -3.13 0.00 0.00 - - -2.42 -0.21 -0.20 -0.22 -0.21 -0.23
Issuance of Debt		 392 0.00 0.00 - - - - - - - -
Issuance of Common Equity		 429 0.00 0.00 - 250 61 57 12 52 0.00 173
Other Financing Activities, net		 52 253 65 11 7.47 8.28 3.58 -0.17 3.12 0.50 13
Cash Income Taxes Paid		 -3.74 0.00 -0.00 -0.00 0.10 -0.30 -0.00 0.00 0.00 0.00 0.01

Quarterly Cash Flow Statements for Arrowhead Pharmaceuticals

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Change in Cash & Equivalents		 -49 29 -58 69 -53 5.40 -30 -67 94 -31 53
Net Cash From Operating Activities		 -146 -137 -115 -92 -118 -26 -21 -32 -76 -69 -69
Net Cash From Continuing Operating Activities		 -146 -137 -115 -92 -118 -26 -21 -32 -76 -69 -69
Net Income / (Loss) Continuing Operations		 -175 -173 -174 -127 -135 -111 -104 48 -42 -86 -72
Consolidated Net Income / (Loss)		 -175 -173 -174 -127 -135 -111 -104 48 -42 -86 -72
Depreciation Expense		 5.24 5.03 4.78 4.53 4.26 3.86 3.28 2.67 2.69 2.66 2.59
Amortization Expense		 -5.70 -11 6.99 1.73 -0.84 -0.99 -0.95 -0.77 0.69 0.90 1.68
Non-Cash Adjustments To Reconcile Net Income		 36 33 22 26 29 68 26 26 23 41 39
Changes in Operating Assets and Liabilities, net		 -6.31 9.59 25 2.75 -15 14 55 -108 -60 -28 -40
Net Cash From Investing Activities		 77 -223 6.95 -269 65 31 -9.91 -36 -81 36 61
Net Cash From Continuing Investing Activities		 77 -223 6.95 -269 65 31 -9.91 -36 -81 36 61
Purchase of Property, Plant & Equipment		 -7.52 -24 -14 -34 -69 -64 -47 -27 -39 -33 -9.54
Purchase of Investments		 -34 -292 -119 -310 0.00 -12 -41 -81 -111 - -75
Sale and/or Maturity of Investments		 118 94 140 75 133 107 78 73 69 69 146
Net Cash From Financing Activities		 21 389 50 431 0.27 0.82 1.14 0.52 251 0.86 61
Net Cash From Continuing Financing Activities		 21 389 50 431 0.27 0.82 1.14 0.52 251 0.86 61
Repayment of Debt		 -5.00 - - - 0.00 - - - - - -
Issuance of Common Equity		 25 - - - 0.00 - - - - - -
Other Financing Activities, net		 0.63 0.22 50 1.51 0.27 0.82 1.14 0.52 251 0.86 61
Cash Income Taxes Paid		 -0.01 -0.68 -0.05 -2.02 -1.00 - - - 0.00 -0.00 -

Annual Balance Sheets for Arrowhead Pharmaceuticals

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 9/30/2024 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019 9/30/2018 9/30/2017 9/30/2016 9/30/2015 9/30/2014
Total Assets		 1,140 766 692 710 523 350 112 104 128 132 183
Total Current Assets		 695 416 405 385 322 265 79 68 91 103 155
Cash & Equivalents		 103 111 108 184 144 222 30 25 85 81 133
Short-Term Investments		 578 293 268 183 172 37 46 41 0.00 18 22
Accounts Receivable		 0.00 - 1.41 10 0.85 0.66 0.33 0.07 0.08 0.00 -
Prepaid Expenses		 9.54 8.81 7.29 4.36 4.25 3.32 1.27 0.87 1.29 3.29 0.59
Other Current Assets		 4.97 4.03 20 2.19 1.78 2.56 0.64 1.36 3.77 0.82 0.05
Plant, Property, & Equipment, net		 386 290 110 49 31 23 14 16 15 4.53 3.87
Total Noncurrent Assets		 58 59 176 277 169 61 19 21 22 25 24
Intangible Assets		 8.56 10 12 14 15 17 19 20 22 25 1.01
Other Noncurrent Operating Assets		 50 49 59 18 16 0.14 0.14 0.14 0.12 0.05 0.04
Total Liabilities & Shareholders' Equity		 1,140 766 692 710 523 350 112 104 128 132 183
Total Liabilities		 949 478 274 301 61 106 16 23 33 23 17
Total Current Liabilities		 103 105 139 147 41 97 12 19 26 16 12
Short-Term Debt		 0.00 - - - - - 0.22 0.21 0.19 0.22 0.26
Accounts Payable		 11 36 2.87 9.46 6.83 7.65 2.81 4.08 12 5.03 2.58
Accrued Expenses		 63 40 47 14 5.39 6.50 5.04 4.56 4.59 5.38 1.40
Current Employee Benefit Liabilities		 22 18 12 9.77 8.06 4.96 3.94 3.40 3.97 3.82 3.27
Other Current Liabilities		 6.77 11 2.78 2.25 1.11 0.02 0.05 0.74 1.65 1.35 4.23
Total Noncurrent Liabilities		 846 373 135 155 20 8.74 4.00 4.45 7.51 6.75 4.98
Long-Term Debt		 393 0.00 - - - - 2.10 2.33 2.53 0.00 -
Capital Lease Obligations		 111 105 - - - - - - - 0.54 0.76
Other Noncurrent Operating Liabilities		 341 268 79 23 20 0.00 0.20 0.20 0.20 6.06 4.23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 191 287 418 409 462 244 95 81 95 110 166
Total Preferred & Common Equity		 185 271 399 409 462 245 96 81 96 110 167
Total Common Equity		 185 271 399 409 462 245 96 81 96 110 167
Common Stock		 1,806 1,301 1,219 1,054 966 664 583 514 494 427 391
Retained Earnings		 -1,626 -1,026 -821 -645 -504 -419 -487 -433 -398 -317 -225
Accumulated Other Comprehensive Income / (Loss)		 4.75 -3.22 -0.14 -0.07 0.02 -0.39 -0.02 0.03 0.01 -0.14 0.00
Noncontrolling Interest		 5.62 16 20 0.00 - -0.56 -0.56 -0.56 -0.56 -0.56 -0.56

Quarterly Balance Sheets for Arrowhead Pharmaceuticals

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 12/31/2024 6/30/2024 3/31/2024 12/31/2023 6/30/2023 3/31/2023 12/31/2022 6/30/2022
Total Assets		 1,014 884 955 626 796 891 891 752
Total Current Assets		 571 450 542 238 470 575 575 432
Cash & Equivalents		 54 69 128 58 105 135 202 139
Short-Term Investments		 499 367 395 162 346 346 300 277
Accounts Receivable		 2.50 - - - 1.25 69 40 0.24
Prepaid Expenses		 9.37 9.21 11 11 10 9.94 8.41 6.76
Other Current Assets		 5.74 4.18 7.51 7.10 7.16 14 25 8.89
Plant, Property, & Equipment, net		 387 376 359 333 231 185 147 72
Total Noncurrent Assets		 56 58 54 55 94 131 169 247
Intangible Assets		 8.14 8.99 9.41 9.84 11 11 12 12
Other Noncurrent Operating Assets		 48 49 45 45 41 41 42 69
Total Liabilities & Shareholders' Equity		 1,014 884 955 626 796 891 891 752
Total Liabilities		 958 545 460 453 414 426 495 278
Total Current Liabilities		 94 97 65 64 70 87 122 128
Short-Term Debt		 1.63 - - - - - - -
Accounts Payable		 14 27 8.52 4.46 7.87 9.56 0.80 5.89
Accrued Expenses		 59 48 37 47 38 40 48 32
Current Employee Benefit Liabilities		 11 16 14 8.78 4.43 5.49 4.09 2.65
Other Current Liabilities		 7.00 6.47 5.86 3.88 2.82 2.71 2.66 2.88
Total Noncurrent Liabilities		 864 448 395 389 344 339 373 149
Long-Term Debt		 408 - - - - - - -
Capital Lease Obligations		 109 112 114 115 80 80 79 -
Other Noncurrent Operating Liabilities		 347 336 281 274 264 258 253 78
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 56 339 495 174 382 465 396 474
Total Preferred & Common Equity		 53 331 484 160 365 447 377 454
Total Common Equity		 53 331 484 160 365 447 377 454
Common Stock		 1,847 1,787 1,769 1,321 1,282 1,261 1,239 1,189
Retained Earnings		 -1,799 -1,455 -1,284 -1,159 -916 -813 -862 -735
Accumulated Other Comprehensive Income / (Loss)		 4.14 -0.99 -1.10 -1.26 -0.41 -0.33 -0.26 -0.14
Noncontrolling Interest		 3.49 8.43 12 13 17 18 19 20

Annual Metrics And Ratios for Arrowhead Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 9/30/2024 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019 9/30/2018 9/30/2017 9/30/2016 9/30/2015 9/30/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -98.52% -1.03% 75.89% 57.16% -47.87% 945.67% -48.60% 19,736.49% -58.55% 118.29% -39.71%
EBITDA Growth		 -204.41% -17.38% -18.77% -58.62% -230.85% 232.30% -67.23% 61.59% 12.02% -56.29% -96.29%
EBIT Growth		 -196.28% -14.47% -20.94% -56.78% -253.20% 210.26% -59.51% 57.56% 11.53% -56.46% -91.28%
NOPAT Growth		 -193.21% -14.84% -19.77% -59.98% -206.84% 255.88% -51.20% 54.74% 14.83% -80.14% -116.66%
Net Income Growth		 -191.34% -18.57% -25.31% -66.58% -224.39% 224.84% -58.38% 57.93% 11.11% -56.56% -85.23%
EPS Growth		 -160.42% -14.97% -22.79% -61.90% -221.74% 206.15% -38.30% 64.93% 16.25% -28.00% 3.85%
Operating Cash Flow Growth		 -200.77% -13.05% -179.46% 278.82% -155.37% 466.42% -97.27% 62.84% 1.95% -85.53% -86.08%
Free Cash Flow Firm Growth		 -128.52% 26.36% -343.58% 182.07% -194.28% 432.37% -35.43% 46.01% 34.89% -208.60% -277.58%
Invested Capital Growth		 220.72% 81.45% 68.75% -2,424.83% 114.95% -379.77% 18.21% 43.66% 6.54% 213.48% -466.60%
Revenue Q/Q Growth		 -81.93% -6.04% -2.68% 28.48% -28.84% 23.43% 18.68% 38.21% -7.32% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.80% -14.58% -12.52% -10.22% -221.92% 46.75% -1.01% 28.08% 3.03% -2.15% -18.48%
EBIT Q/Q Growth		 -10.59% -13.29% -12.13% -10.38% -180.66% 51.52% -0.51% 24.67% 3.08% -2.49% -18.17%
NOPAT Q/Q Growth		 -9.85% -13.57% -11.88% -10.99% -178.91% 51.15% -1.67% 23.78% 4.04% -3.09% -36.88%
Net Income Q/Q Growth		 -11.39% -13.61% -14.66% -11.87% -246.32% 49.37% -0.05% 25.05% 3.00% -2.58% -17.22%
EPS Q/Q Growth		 -7.30% -12.94% -12.84% -10.57% -236.00% 46.81% 5.80% 29.85% 4.29% 1.84% -30.21%
Operating Cash Flow Q/Q Growth		 -31.66% 21.76% -48.90% -6.94% -35.44% 10.53% 12.14% 3.92% 2.77% -1.70% -18.49%
Free Cash Flow Firm Q/Q Growth		 -3.95% 3.19% -25.72% -23.12% -9.63% 3.50% 10.76% 4.75% -0.33% -2.72% -24.79%
Invested Capital Q/Q Growth		 -0.22% 63.59% 40.94% 1.56% -68.60% 15.68% -19.06% 4.74% -31.58% -41.69% -545.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -16,543.99% -80.17% -67.59% -100.11% -99.19% 39.51% -312.31% -95.98% -49,575.55% -23,356.26% -32,621.89%
Operating Margin		 -16,927.06% -85.16% -73.39% -107.77% -105.87% 36.25% -346.52% -117.79% -51,627.09% -25,124.08% -30,443.59%
EBIT Margin		 -16,976.29% -84.52% -73.08% -106.28% -106.53% 36.25% -343.80% -110.78% -51,780.99% -24,258.54% -33,844.49%
Profit (Net Income) Margin		 -17,169.61% -86.93% -72.56% -101.85% -96.09% 40.27% -337.32% -109.46% -51,614.64% -24,068.29% -33,557.38%
Tax Burden Percent		 99.55% 101.35% 102.19% 100.00% 100.00% 99.74% 100.00% 100.01% 100.00% 100.00% 100.01%
Interest Burden Percent		 101.60% 101.49% 97.17% 95.84% 90.20% 111.37% 98.11% 98.81% 99.68% 99.21% 99.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -34,263.52% 0.00% 0.00% 0.00% 0.00% 0.00% -201.70% -171.63% -476.61% -9,727.21% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -34,184.09% 0.00% 0.00% 0.00% 0.00% 0.00% -179.42% -159.98% -449.48% -9,709.16% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 34,008.54% 0.00% 0.00% 0.00% 0.00% 0.00% 139.86% 132.54% 396.74% 9,660.50% 0.00%
Return on Equity (ROE)		 -254.98% -59.33% -42.67% -32.36% -23.96% 40.07% -61.84% -39.09% -79.87% -66.72% -61.26%
Cash Return on Invested Capital (CROIC)		 -3,122.72% 0.00% 0.00% 0.00% -1,509.88% 0.00% -218.39% -207.46% -482.94% -765.99% 0.00%
Operating Return on Assets (OROA)		 -63.28% -27.92% -25.35% -23.85% -21.49% 26.52% -51.47% -29.97% -62.96% -58.82% -53.81%
Return on Assets (ROA)		 -64.00% -28.72% -25.18% -22.85% -19.39% 29.46% -50.50% -29.61% -62.76% -58.36% -53.35%
Return on Common Equity (ROCE)		 -243.55% -56.33% -41.65% -32.36% -23.98% 40.20% -62.23% -39.34% -80.30% -66.99% -62.00%
Return on Equity Simple (ROE_SIMPLE)		 -328.77% -77.13% -44.29% -34.45% -18.31% 27.79% -56.84% -42.22% -85.50% -83.45% -35.26%
Net Operating Profit after Tax (NOPAT)		 -421 -144 -125 -104 -65 61 -39 -26 -57 -67 -37
NOPAT Margin		 -11,848.94% -59.61% -51.37% -75.44% -74.11% 36.16% -242.56% -82.45% -36,138.97% -17,586.85% -21,310.51%
Net Nonoperating Expense Percent (NNEP)		 -79.42% -16.84% -9.41% -6.85% -5.12% 3.68% -22.28% -11.64% -27.13% -18.06% -21.04%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,781.22% 38.44% 51.16% 58.56% 59.41% 15.73% 118.38% 55.72% 14,902.07% 6,409.74% 10,699.06%
R&D to Revenue		 14,245.85% 146.71% 122.23% 149.21% 146.46% 48.02% 328.13% 162.08% 39,232.39% 15,028.83% 13,221.74%
Operating Expenses to Revenue		 17,027.06% 185.16% 173.39% 207.77% 205.87% 63.75% 446.52% 217.79% 51,727.09% 25,224.08% 30,543.59%
Earnings before Interest and Taxes (EBIT)		 -603 -203 -178 -147 -94 61 -55 -35 -82 -93 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -587 -193 -164 -138 -87 67 -50 -30 -78 -89 -57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 12.99 10.61 8.78 15.92 9.54 10.98 17.61 3.98 4.67 3.11 4.69
Price to Tangible Book Value (P/TBV)		 13.61 11.03 9.05 16.47 9.87 11.80 21.91 5.31 6.08 4.02 4.72
Price to Revenue (P/Rev)		 678.12 11.96 14.38 47.07 50.06 15.91 104.53 10.31 2,820.10 897.19 4,465.48
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 39.51 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 2.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 156.29 0.00 0.00 0.00 449.11 0.00 76.67 14.62 29.33 21.00 0.00
Enterprise Value to Revenue (EV/Rev)		 629.92 10.79 12.48 42.63 44.91 14.11 99.90 8.28 2,294.66 639.20 3,455.28
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 35.71 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 38.93 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 39.03 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 34.41 0.00 13.77 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 54.07 0.00 16.91 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 2.64 0.36 0.00 0.00 0.00 0.00 0.02 0.03 0.03 0.01 0.01
Long-Term Debt to Equity		 2.64 0.36 0.00 0.00 0.00 0.00 0.02 0.03 0.03 0.00 0.00
Financial Leverage		 -0.99 -1.11 -1.32 -1.22 -1.07 -1.11 -0.78 -0.83 -0.88 -1.00 -1.06
Leverage Ratio		 3.98 2.07 1.70 1.42 1.24 1.36 1.22 1.32 1.27 1.14 1.15
Compound Leverage Factor		 4.05 2.10 1.65 1.36 1.11 1.51 1.20 1.30 1.27 1.13 1.14
Debt to Total Capital		 72.52% 26.70% 0.00% 0.00% 0.00% 0.00% 2.38% 3.04% 2.79% 0.69% 0.61%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.23% 0.25% 0.20% 0.20% 0.16%
Long-Term Debt to Total Capital		 72.52% 26.70% 0.00% 0.00% 0.00% 0.00% 2.15% 2.79% 2.59% 0.49% 0.45%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.81% 4.04% 4.74% 0.00% 0.00% -0.23% -0.57% -0.67% -0.57% -0.50% -0.33%
Common Equity to Total Capital		 26.67% 69.26% 95.26% 100.00% 100.00% 100.23% 98.19% 97.63% 97.78% 99.82% 99.72%
Debt to EBITDA		 -0.86 -0.54 0.00 0.00 0.00 0.00 -0.05 -0.08 -0.03 -0.01 -0.02
Net Debt to EBITDA		 0.30 1.55 0.00 0.00 0.00 0.00 1.47 2.09 1.05 1.10 3.09
Long-Term Debt to EBITDA		 -0.86 -0.54 0.00 0.00 0.00 0.00 -0.04 -0.08 -0.03 -0.01 -0.01
Debt to NOPAT		 -1.20 -0.73 0.00 0.00 0.00 0.00 -0.06 -0.10 -0.05 -0.01 -0.03
Net Debt to NOPAT		 0.42 2.08 0.00 0.00 0.00 0.00 1.90 2.44 1.44 1.46 4.73
Long-Term Debt to NOPAT		 -1.20 -0.73 0.00 0.00 0.00 0.00 -0.05 -0.09 -0.04 -0.01 -0.02
Altman Z-Score		 -1.59 1.66 5.98 11.60 42.39 15.19 54.96 2.33 2.23 4.21 26.01
Noncontrolling Interest Sharing Ratio		 4.48% 5.05% 2.40% 0.00% -0.08% -0.33% -0.63% -0.63% -0.54% -0.40% -1.21%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.74 3.95 2.92 2.62 7.92 2.73 6.37 3.63 3.53 6.47 13.07
Quick Ratio		 6.60 3.83 2.72 2.58 7.78 2.67 6.22 3.51 3.33 6.21 13.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -447 -196 -266 109 -133 141 -42 -31 -58 -89 -29
Operating Cash Flow to CapEx		 -327.17% -87.07% -257.94% 726.91% -801.55% 1,441.84% -3,322.66% -302.33% -1,669.00% -548.93% -2,074.33%
Free Cash Flow to Firm to Interest Expense		 -13.81 -10.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -14.31 -8.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -18.68 -18.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.33 0.35 0.22 0.20 0.73 0.15 0.27 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 41.70 24.91 116.75 341.44 81.70 439.89 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.01 1.20 3.06 3.48 3.25 9.09 1.10 2.03 0.02 0.09 0.05
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 8.75 14.65 3.13 1.07 4.47 0.83 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 8.75 14.65 3.13 1.07 4.47 0.83 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 14 -12 -64 -205 8.80 -59 21 18 12 12 -10
Invested Capital Turnover		 2.89 -6.35 -1.81 -1.41 -3.52 -8.93 0.83 2.08 0.01 0.55 -0.03
Increase / (Decrease) in Invested Capital		 26 52 141 -213 68 -80 3.24 5.41 0.76 22 -8.44
Enterprise Value (EV)		 2,237 2,597 3,036 5,896 3,952 2,382 1,613 260 363 244 605
Market Capitalization		 2,408 2,880 3,498 6,509 4,405 2,686 1,687 324 447 343 781
Book Value per Share		 $1.49 $2.53 $3.77 $3.92 $4.51 $2.57 $1.09 $1.09 $1.57 $1.85 $3.15
Tangible Book Value per Share		 $1.42 $2.44 $3.65 $3.79 $4.36 $2.39 $0.88 $0.82 $1.21 $1.43 $3.13
Total Capital		 695 392 418 409 462 244 98 83 98 110 167
Total Debt		 504 105 0.00 0.00 0.00 0.00 2.33 2.53 2.73 0.76 1.02
Total Long-Term Debt		 504 105 0.00 0.00 0.00 0.00 2.10 2.33 2.53 0.54 0.76
Net Debt		 -177 -299 -482 -613 -453 -303 -74 -63 -83 -98 -176
Capital Expenditures (CapEx)		 141 177 53 24 12 12 1.42 7.92 3.86 12 1.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -89 -93 -110 -130 -34 -91 -9.91 -16 -20 -12 -11
Debt-free Net Working Capital (DFNWC)		 592 311 266 238 282 168 67 49 65 87 143
Net Working Capital (NWC)		 592 311 266 238 282 168 66 49 65 87 143
Net Nonoperating Expense (NNE)		 189 66 52 37 19 -6.94 15 8.48 25 25 21
Net Nonoperating Obligations (NNO)		 -177 -299 -482 -613 -453 -303 -74 -63 -83 -98 -176
Total Depreciation and Amortization (D&A)		 15 10 13 8.53 6.47 5.51 5.08 4.65 3.49 3.45 2.14
Debt-free, Cash-free Net Working Capital to Revenue		 -2,496.71% -38.47% -45.20% -93.81% -38.42% -53.63% -61.37% -51.57% -12,829.54% -3,027.78% -6,254.80%
Debt-free Net Working Capital to Revenue		 16,679.89% 129.19% 109.55% 172.15% 320.13% 99.63% 412.75% 157.32% 41,086.23% 22,824.12% 81,838.71%
Net Working Capital to Revenue		 16,679.89% 129.19% 109.55% 172.15% 320.13% 99.63% 411.36% 156.66% 40,963.51% 22,767.17% 81,687.85%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.00) ($1.92) ($1.67) ($1.36) ($0.84) $0.72 ($0.65) ($0.47) ($1.34) ($1.60) ($1.25)
Adjusted Weighted Average Basic Shares Outstanding		 119.78M 106.75M 105.43M 103.75M 100.72M 93.86M 92.22M 74.83M 74.17M 59.55M 54.68M
Adjusted Diluted Earnings per Share		 ($5.00) ($1.92) ($1.67) ($1.36) ($0.84) $0.69 ($0.65) ($0.47) ($1.34) ($1.60) ($1.25)
Adjusted Weighted Average Diluted Shares Outstanding		 119.78M 106.75M 105.43M 103.75M 100.72M 98.61M 92.22M 74.83M 74.17M 59.55M 54.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.65) ($0.47) ($1.34) ($1.60) ($1.25)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 124.43M 107.43M 106.01M 104.53M 102.76M 95.71M 83.64M 73.90M 61.05M 57.36M 46.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -421 -144 -125 -104 -65 61 -39 -26 -60 -66 -34
Normalized NOPAT Margin		 -11,848.94% -59.61% -51.37% -75.44% -74.11% 36.16% -242.56% -82.45% -37,824.12% -17,240.24% -19,467.75%
Pre Tax Income Margin		 -17,247.54% -85.78% -71.01% -101.85% -96.09% 40.37% -337.30% -109.46% -51,613.12% -24,067.67% -33,554.35%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -18.63 -11.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -13.01 -7.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -23.01 -20.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -17.38 -17.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Arrowhead Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -29.60% 0.00% -100.00% -100.00% -94.32% -49.02% -51.18% -3.65% 127.95% -17.52% -29.37%
EBITDA Growth		 -21.74% -63.67% -63.50% -339.16% -246.94% -30.63% -45.01% 7.64% 38.04% -29.56% -135.86%
EBIT Growth		 -18.33% -53.63% -71.28% -361.56% -227.01% -28.51% -39.72% 11.22% 34.99% -29.79% -134.86%
NOPAT Growth		 -18.21% -49.73% -71.51% -283.40% -224.07% -29.23% -40.86% 15.91% 33.46% -29.20% -128.78%
Net Income Growth		 -29.43% -56.14% -67.08% -366.37% -223.78% -29.17% -44.53% 7.46% 33.50% -35.61% -140.76%
EPS Growth		 -12.10% -33.33% -43.75% -326.67% -217.95% -27.50% -41.18% 9.76% 35.00% -31.15% -134.48%
Operating Cash Flow Growth		 -24.13% -429.26% -455.51% -191.68% -56.05% 62.28% 69.81% -150.49% -23.17% -186.06% -132.40%
Free Cash Flow Firm Growth		 78.35% -9.23% -15.34% -113.73% -386.57% 35.83% 2.01% -533.22% -137.18% -218.68% -170.53%
Invested Capital Growth		 -68.15% 220.72% 144.04% 685.99% 148.39% 81.45% 69.91% 90.30% 19.06% 68.75% 47.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% -77.94% 1.72% -89.18% 133.86% 98.09% -2.58% -78.65%
EBITDA Q/Q Growth		 5.77% -4.78% -36.63% 9.76% -26.69% -4.67% -299.86% 230.91% 52.30% -16.19% -248.36%
EBIT Q/Q Growth		 2.57% 5.74% -39.19% 7.44% -26.49% -5.09% -312.56% 215.73% 50.29% -14.26% -269.20%
NOPAT Q/Q Growth		 0.49% 7.91% -39.58% 7.58% -26.05% -5.48% -249.26% 263.31% 49.74% -14.98% -222.82%
Net Income Q/Q Growth		 -1.08% 0.36% -36.99% 6.19% -21.94% -6.62% -318.40% 214.03% 51.35% -19.29% -262.39%
EPS Q/Q Growth		 -2.21% 1.45% -35.29% 17.74% -21.57% -6.25% -313.33% 215.38% 51.25% -17.65% -265.85%
Operating Cash Flow Q/Q Growth		 -6.60% -18.89% -24.94% 21.61% -354.52% -24.78% 34.40% 58.06% -9.86% 0.11% -209.70%
Free Cash Flow Firm Q/Q Growth		 52.58% 17.92% 9.91% 38.25% -139.19% 13.32% -66.95% -40.58% 68.45% -32.35% -978.84%
Invested Capital Q/Q Growth		 52.67% -0.22% -83.31% 25.27% 678.54% 63.59% -122.09% 89.66% -121.75% 40.94% 28.42%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -6,461.60% 0.00% 0.00% 0.00% -3,736.86% -650.69% -632.35% 34.23% -61.15% -253.94% -212.91%
Operating Margin		 -6,456.48% 0.00% 0.00% 0.00% -3,845.25% -672.98% -648.99% 32.93% -67.36% -265.49% -224.94%
EBIT Margin		 -6,442.84% 0.00% 0.00% 0.00% -3,833.40% -668.53% -647.06% 32.94% -66.55% -265.21% -226.11%
Profit (Net Income) Margin		 -7,008.72% 0.00% 0.00% 0.00% -3,812.33% -689.66% -657.98% 32.60% -66.85% -272.18% -222.28%
Tax Burden Percent		 100.06% 100.32% 100.00% 100.00% 97.61% 101.86% 100.72% 100.00% 100.04% 104.61% 100.00%
Interest Burden Percent		 108.72% 104.52% 99.20% 100.79% 101.88% 101.28% 100.96% 98.97% 100.40% 98.11% 98.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -249.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -160.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 97.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -152.50% 0.00% -151.84% 0.00% -106.24% -59.33% -43.03% -33.17% -40.43% -42.67% -33.79%
Cash Return on Invested Capital (CROIC)		 -865.57% -3,122.72% -2,997.65% -503.04% -612.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -19.64% 0.00% 0.00% 0.00% -918.03% -220.84% -214.24% 11.27% -24.21% -92.02% -76.02%
Return on Assets (ROA)		 -21.37% 0.00% 0.00% 0.00% -912.99% -227.82% -217.86% 11.15% -24.32% -94.44% -74.74%
Return on Common Equity (ROCE)		 -141.36% 0.00% -146.46% 0.00% -100.16% -56.33% -41.15% -32.50% -39.41% -41.65% -33.04%
Return on Equity Simple (ROE_SIMPLE)		 -1,235.12% 0.00% -165.59% -98.70% -188.79% 0.00% -50.49% -34.05% -41.22% 0.00% -33.91%
Net Operating Profit after Tax (NOPAT)		 -113 -114 -123 -88 -96 -76 -72 48 -29 -59 -51
NOPAT Margin		 -4,519.54% 0.00% 0.00% 0.00% -2,691.68% -471.09% -454.29% 32.93% -47.16% -185.85% -157.46%
Net Nonoperating Expense Percent (NNEP)		 -89.32% -25.14% -13.71% -8.70% -12.37% -9.01% -6.47% -0.09% -2.27% -4.98% -3.42%
Return On Investment Capital (ROIC_SIMPLE)		 -19.66% - - - -33.09% - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,076.40% 0.00% 0.00% 0.00% 664.74% 152.65% 150.21% 15.88% 33.55% 101.43% 102.25%
R&D to Revenue		 5,480.08% 0.00% 0.00% 0.00% 3,280.51% 620.33% 598.78% 51.19% 133.81% 264.06% 222.70%
Operating Expenses to Revenue		 6,556.48% 0.00% 0.00% 0.00% 3,945.25% 772.98% 748.99% 67.07% 167.36% 365.49% 324.94%
Earnings before Interest and Taxes (EBIT)		 -161 -165 -175 -126 -136 -108 -102 48 -42 -84 -73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -162 -171 -164 -120 -133 -105 -100 50 -38 -80 -69
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 44.48 12.99 9.77 7.32 20.45 10.61 10.45 6.16 11.40 8.78 8.20
Price to Tangible Book Value (P/TBV)		 52.63 13.61 10.04 7.47 21.78 11.03 10.76 6.31 11.76 9.05 8.43
Price to Revenue (P/Rev)		 935.75 678.12 164.29 99.89 18.05 11.96 14.88 10.08 15.45 14.38 14.90
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 105.66 156.29 203.01 36.61 46.48 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 923.45 629.92 148.20 88.68 17.54 10.79 13.33 8.39 13.58 12.48 12.65
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 9.25 2.64 0.33 0.23 0.66 0.36 0.21 0.17 0.20 0.00 0.00
Long-Term Debt to Equity		 9.22 2.64 0.33 0.23 0.66 0.36 0.21 0.17 0.20 0.00 0.00
Financial Leverage		 -0.61 -0.99 -1.03 -0.93 -1.13 -1.11 -1.16 -1.18 -1.41 -1.32 -1.35
Leverage Ratio		 7.14 3.98 2.33 1.92 2.66 2.07 1.81 1.74 1.99 1.70 1.63
Compound Leverage Factor		 7.76 4.16 2.31 1.94 2.71 2.09 1.83 1.72 2.00 1.66 1.60
Debt to Total Capital		 90.24% 72.52% 24.84% 18.66% 39.86% 26.70% 17.30% 14.69% 16.70% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 89.96% 72.52% 24.84% 18.66% 39.86% 26.70% 17.30% 14.69% 16.70% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.61% 0.81% 1.87% 1.91% 4.61% 4.04% 3.71% 3.36% 4.06% 4.74% 4.27%
Common Equity to Total Capital		 9.15% 26.67% 73.29% 79.44% 55.53% 69.26% 78.99% 81.95% 79.24% 95.26% 95.73%
Debt to EBITDA		 -0.84 -0.86 -0.22 -0.25 -0.40 -0.54 -0.47 -0.58 -0.56 0.00 0.00
Net Debt to EBITDA		 0.06 0.30 0.62 0.90 0.37 1.55 2.46 3.49 3.82 0.00 0.00
Long-Term Debt to EBITDA		 -0.84 -0.86 -0.22 -0.25 -0.40 -0.54 -0.47 -0.58 -0.56 0.00 0.00
Debt to NOPAT		 -1.18 -1.20 -0.29 -0.34 -0.55 -0.73 -0.63 -0.76 -0.72 0.00 0.00
Net Debt to NOPAT		 0.08 0.42 0.85 1.23 0.50 2.08 3.28 4.55 4.89 0.00 0.00
Long-Term Debt to NOPAT		 -1.18 -1.20 -0.29 -0.34 -0.55 -0.73 -0.63 -0.76 -0.72 0.00 0.00
Altman Z-Score		 -0.98 -0.33 1.10 2.94 1.66 2.07 4.41 3.74 4.62 6.43 7.17
Noncontrolling Interest Sharing Ratio		 7.31% 0.00% 3.55% 0.00% 5.73% 5.05% 4.37% 2.00% 2.51% 2.40% 2.22%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.09 6.74 4.65 8.31 3.73 3.95 6.69 6.60 4.71 2.92 3.37
Quick Ratio		 5.92 6.60 4.52 8.03 3.46 3.83 6.45 6.32 4.44 2.72 3.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -66 -140 -170 -189 -306 -128 -148 -88 -63 -199 -151
Operating Cash Flow to CapEx		 -1,946.14% -564.93% -798.80% -271.10% -171.64% -40.57% -44.58% -115.95% -194.07% -210.13% -721.63%
Free Cash Flow to Firm to Interest Expense		 -3.06 -9.54 -33.41 -26.08 -57.00 -24.31 -28.61 -17.48 -22.07 0.00 0.00
Operating Cash Flow to Interest Expense		 -6.76 -9.37 -22.66 -12.75 -21.96 -4.93 -4.03 -6.26 -26.51 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -7.10 -11.03 -25.49 -17.46 -34.75 -17.07 -13.06 -11.66 -40.16 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.02 0.04 0.24 0.33 0.33 0.34 0.36 0.35 0.34
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 344.84 7.71 14.02 41.70 549.31
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.01 0.01 0.06 0.13 0.76 1.20 1.69 2.27 2.79 3.06 4.18
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 1.06 47.33 26.04 8.75 0.66
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 1.06 47.33 26.04 8.75 0.66
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 22 14 14 86 69 -12 -33 -15 -142 -64 -108
Invested Capital Turnover		 0.06 2.89 -2.16 1.00 -4.97 -6.35 -3.64 -3.29 -1.76 -1.81 -1.58
Increase / (Decrease) in Invested Capital		 -47 26 47 101 210 52 76 137 33 141 100
Enterprise Value (EV)		 2,309 2,237 2,912 3,146 3,188 2,597 3,415 2,290 3,781 3,036 3,161
Market Capitalization		 2,339 2,408 3,228 3,543 3,280 2,880 3,812 2,751 4,300 3,498 3,723
Book Value per Share		 $0.42 $1.49 $2.66 $3.90 $1.49 $2.53 $3.41 $4.12 $3.56 $3.77 $4.29
Tangible Book Value per Share		 $0.36 $1.42 $2.59 $3.83 $1.40 $2.44 $3.31 $4.02 $3.45 $3.65 $4.18
Total Capital		 575 695 451 609 289 392 462 545 476 418 474
Total Debt		 519 504 112 114 115 105 80 80 79 0.00 0.00
Total Long-Term Debt		 517 504 112 114 115 105 80 80 79 0.00 0.00
Net Debt		 -34 -177 -325 -409 -105 -299 -415 -480 -538 -482 -582
Capital Expenditures (CapEx)		 7.52 24 14 34 69 64 47 27 39 33 9.54
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -75 -89 -83 -47 -46 -93 -52 6.65 -49 -110 -112
Debt-free Net Working Capital (DFNWC)		 478 592 353 476 174 311 400 488 453 266 304
Net Working Capital (NWC)		 477 592 353 476 174 311 400 488 453 266 304
Net Nonoperating Expense (NNE)		 62 60 51 39 40 35 32 0.49 12 27 21
Net Nonoperating Obligations (NNO)		 -34 -177 -325 -409 -105 -299 -415 -480 -538 -482 -582
Total Depreciation and Amortization (D&A)		 -0.47 -6.11 12 6.26 3.43 2.87 2.33 1.90 3.38 3.56 4.28
Debt-free, Cash-free Net Working Capital to Revenue		 -2,981.28% -2,496.71% -424.08% -131.48% -25.37% -38.47% -20.20% 2.44% -17.55% -45.20% -44.94%
Debt-free Net Working Capital to Revenue		 19,136.12% 16,679.89% 1,798.39% 1,343.20% 95.84% 129.19% 156.10% 178.76% 162.75% 109.55% 121.70%
Net Working Capital to Revenue		 19,071.12% 16,679.89% 1,798.39% 1,343.20% 95.84% 129.19% 156.10% 178.76% 162.75% 109.55% 121.70%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.39) ($1.36) ($1.38) ($1.02) ($1.24) ($1.03) ($0.96) $0.46 ($0.39) ($0.81) ($0.68)
Adjusted Weighted Average Basic Shares Outstanding		 124.85M 119.78M 124.20M 123.29M 107.42M 106.75M 107.00M 106.76M 106.04M 105.43M 105.75M
Adjusted Diluted Earnings per Share		 ($1.39) ($1.36) ($1.38) ($1.02) ($1.24) ($1.02) ($0.96) $0.45 ($0.39) ($0.80) ($0.68)
Adjusted Weighted Average Diluted Shares Outstanding		 124.85M 119.78M 124.20M 123.29M 107.42M 106.75M 107.00M 108.14M 106.04M 105.43M 105.75M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 126.10M 124.43M 124.32M 124.20M 123.90M 107.43M 107.19M 106.90M 108.31M 106.01M 105.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -113 -114 -123 -88 -96 -76 -72 34 -29 -59 -51
Normalized NOPAT Margin		 -4,519.54% 0.00% 0.00% 0.00% -2,691.68% -471.09% -454.29% 23.05% -47.16% -185.85% -157.46%
Pre Tax Income Margin		 -7,004.60% 0.00% 0.00% 0.00% -3,905.63% -677.08% -653.29% 32.60% -66.82% -260.20% -222.28%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -7.44 -11.29 -34.43 -17.39 -25.36 -20.45 -19.85 9.53 -14.61 0.00 0.00
NOPAT to Interest Expense		 -5.22 -7.75 -24.20 -12.19 -17.81 -14.41 -13.94 9.52 -10.35 0.00 0.00
EBIT Less CapEx to Interest Expense		 -7.79 -12.95 -37.27 -22.10 -38.16 -32.60 -28.89 4.12 -28.27 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -5.57 -9.41 -27.04 -16.90 -30.60 -26.56 -22.97 4.12 -24.01 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Arrowhead Pharmaceuticals' Financials

When does Arrowhead Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Arrowhead Pharmaceuticals' financial year ends in September. Their financial year 2024 ended on September 30, 2024.

How has Arrowhead Pharmaceuticals' net income changed over the last 10 years?

Arrowhead Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$609.69 million in 2024, rising from -$58.73 million in 2014. The previous period was -$209.28 million in 2023. Find out what analysts predict for Arrowhead Pharmaceuticals in the coming months.

What is Arrowhead Pharmaceuticals's operating income?
Arrowhead Pharmaceuticals's total operating income in 2024 was -$601.08 million, based on the following breakdown:
  • Total Gross Profit: $3.55 million
  • Total Operating Expenses: $604.63 million
How has Arrowhead Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Arrowhead Pharmaceuticals' total revenue changed from $175 thousand in 2014 to $3.55 million in 2024, a change of 1,929.1%.

How much debt does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals' total liabilities were at $948.74 million at the end of 2024, a 98.3% increase from 2023, and a 5,536.7% increase since 2014.

How much cash does Arrowhead Pharmaceuticals have?

In the past 10 years, Arrowhead Pharmaceuticals' cash and equivalents has ranged from $24.84 million in 2017 to $221.80 million in 2019, and is currently $102.69 million as of their latest financial filing in 2024.

How has Arrowhead Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Arrowhead Pharmaceuticals' book value per share changed from 3.15 in 2014 to 1.49 in 2024, a change of -52.6%.


Related Companies

This page (NASDAQ:ARWR) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
The one deadline Elon can't afford to miss...
For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...
Brownstone Research | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored